[PI3K and mTOR pathway and molecular targeted agents].
Molecular alteration of PI3K and mTOR pathways is frequently detected in various types of cancers. PIK3CA mutations are the predictive markers for anti-EGFR antibodies, trastuzumab, and lapatinib. The p110 isoform selective PI3K inhibitors has been developed in the clinical settings to reduced off-target induced adverse events. Feedback loop for PI3K signal leads the resistance to PI3K inhibitors. Dual PI3K/mTOR inhibitors and mutation selective PI3K inhibitors are under evaluation to circumvent the resistance.
Kazuto
K
Nishio
Kazuko
K
Sakai
Yosuke
Y
Togashi
D000818:Animals; D061067:Antibodies, Monoclonal, Humanized; D058534:Class I Phosphatidylinositol 3-Kinases; D055808:Drug Discovery; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000276:immunology; D006801:Humans; D000077341:Lapatinib; D058990:Molecular Targeted Therapy; D009154:Mutation; D009369:Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000628:therapy*; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000502:physiology*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011799:Quinazolines; D015398:Signal Transduction / Q000235:genetics / Q000502:physiology; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology*; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D058534:Class I Phosphatidylinositol 3-Kinases; D004791:Enzyme Inhibitors; D066246:ErbB Receptors; D000077341:Lapatinib; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011799:Quinazolines; D058570:TOR Serine-Threonine Kinases; D000068878:Trastuzumab; C484760:PIK3CA protein, human